Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27453036 | 0.82 | ACHE (0.52) | HTR2AALDH1A1CYP3A4ACHE | |
| SCHEMBL10922327 | 0.79 | HTR2A (0.47) | HTR2AALDH1A1CYP3A4ACHE | |
| SCHEMBL9116596 | 0.77 | ACHE (0.46) | HTR2AALDH1A1CYP3A4ACHE | |
| SCHEMBL16056216 | 0.75 | ACHE (0.44) | HTR2AALDH1A1CYP3A4ACHETAAR1 | |
| SCHEMBL28637918 | 0.75 | ALDH1A1 (0.51) | HTR2AALDH1A1CYP3A4ACHE | |
| SCHEMBL3207574 | 0.74 | ACHE (0.56) | ALDH1A1CYP3A4ACHE | |
| SCHEMBL2386941 | 0.74 | ACHE (0.56) | ALDH1A1CYP3A4ACHETAAR1 | |
| SCHEMBL24899349 | 0.74 | SLC13A5 (0.49) | HTR2AALDH1A1ACHE | |
| SCHEMBL11288361 | 0.74 | ACHE (0.60) | ALDH1A1CYP3A4ACHE | |
| SCHEMBL1442609 | 0.73 | ACHE (0.46) | HTR2AALDH1A1CYP3A4ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240174603-A1 | MODULATORS OF PROTEIN PHOSPHATASE 2A (PP2A) AND METHODS USING SAME | RAPPTA THERAPEUTICS OY (FI) | 2024-05-30 | — | — | US | disclosed |
| EP-4288412-A1 | MODULATORS OF PROTEIN PHOSPHATASE 2A (PP2A) AND METHODS USING SAME | Rappta Therapeutics Oy (FI) | 2023-12-13 | — | — | EP | disclosed |
| WO-2022167866-A1 | MODULATORS OF PROTEIN PHOSPHATASE 2A (PP2A) AND METHODS USING SAME | RAPPTA THERAPEUTICS OY (FI) | 2022-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240174603-A1 | MODULATORS OF PROTEIN PHOSPHATASE 2A (PP2A) AND METHODS USING SAME | PPM1A, PPP2CA, PPP3CA | HTR2A 2089/4885ALDH1A1 1616/4885CYP3A4 4298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.